These injectable medications have become the standard of care for retinal diseases. The very first injection of the new treatment for exudative macular degeneration was performed at HMRI in 1993. Clinical trials run at HMRI have led to FDA approval by the FDA of revolutionary new treatments for retinal diseases, including the most revolutionary treatment for exudative macular degeneration, diabetic retinopathy, and blood vessel occlusions in the retina. HMRI has now participated in over 60 multi-centered clinical trials. Raymond Wee.Īll doctors have taken on the role of Principal Investigator for clinical trials. The other doctors supporting HMRI are Dr. Kokame trained at the renowned Bascom Palmer Eye Institute, which has been rated the number one eye institute for the past 20 years. Sarah Read is the assistant medical director of HMRI. HMRI consistently participates in the latest multi-centered national and international clinical trials for the development of new treatments for retinal diseases such as macular degeneration, diabetic retinopathy, and retinal vein occlusions.ĭr. The research program of HMRI has developed worldwide recognition with presentations at major meetings around the world and publications in the leading research journals in ophthalmology. This academic program has brought world renowned leaders in the retinal field to Hawaii to speak. Gregg Kokame was the initial founder and remains the medical director of the research and educational programs. This center has allowed retinal research to be a center of excellence for the Pali Momi Medical Center and allowed our research program to make use of hospital resources, the Pali Momi foundation and continuing medical education programs. The Retina Center at Pali Momi is a hospital-based research program affiliated with Hawaii Pacific Health. HMRI is an affiliate of The Retina Center at Pali Momi and Retina Consultants of Hawaii. Hawaii Macula and Retina Institute (HMRI) was established in 1993 as a center of excellence for the study of retinal diseases.
0 kommentar(er)
